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Abstract 
The  blue  rubber  bleb  nevus  syndrome
(BRBNS, syn. bean syndrome) is a rare dise  -
ase characterized by multiple cutaneous and
gastrointestinal venous malformations associ-
ated with severe bleeding. However, the under-
lying molecular mechanisms are unknown and
no  targeted  therapeutic  approach  exists  to
date. Here we report the case of a 19-year-old
male patient with severe BRBNS in whom we
analyzed  the  expression  of  tyrosine  kinases
frequently involved in tumor development by
immunohistochemistry  (vascular  endothelial
growth factor receptor-2, stem cell growth fac-
tor  receptor  (c-kit),  platelet-derived  growth
factor  receptor-β,  and  stem  cell  tyrosine
kinase-1). A prominent expression of c-kit was
detectable in smaller blood vessels, which also
showed a moderate expression of the prolifer-
ation marker MIB1. Surprisingly, other growth
factor receptors stained negatively. We there-
fore conclude that pharmacological inhibition
of  the  c-kit  signaling  pathway  in  cavernous
hemangiomas  by  selective  kinase  inhibitors
may offer options in the treatment of BRBNS
patients. 
Introduction
The  blue  rubber  bleb  nevus  syndrome
(BRBNS) is a rare vascular syndrome charac-
terized  by  venous  malformations  (cavernous
hemangiomas)  in  the  skin,  gastrointestinal
tract, and less frequently in the liver, spleen,
lung, and nervous system.
1,2 In cases where the
skin is affected, extensive plum-purple papules
and nodules are located predominantly on the
upper  extremities  and  the  trunk.  About  200
BRBNS cases have been reported in the litera-
ture to date. Main clinical complications espe-
cially in gastrointestinal lesions are chronic and
acute hemorrhage with consequent iron defi-
ciency,  anemia,  and  death.
3-5 However,  the
underlying molecular mechanisms responsible
for the uncontrolled growth of venous blood ves-
sels are not known. In one case, a gain-of-func-
tion  mutation  in  TIE2  (syn.  TEK  tyrosine
kinase, endothelial) was detected in a patient
with pancreatic lymphangioma associated with
BRBNS;
6 however, it is unclear whether aber-
rant expression or activation of tyrosine kin  ases
is a general relevant mechanism in the patho-
genesis of BRBNS. In this context, administra-
tion  of  highly  selective  tyrosine  kinase
inhibitors  would  offer  novel  pharmacological
options in the treatment of BRBNS patients. 
Materials and Methods
Specimens (2 cm in diameter) of a venous
malformation from a 19-year-old patient were
obtained. After paraffin embedding, 5 µm-sec-
tions  were  stained  immunohistochemically
using  antibodies  recognizing  vascular
endothelial growth factor receptor 2 (VEGFR2,
1:200,  R&D-Systems,  Wiesbaden,  Germany),
stem cell growth factor receptor (c-kit, 1:20,
Dako,  Hamburg,  Germany),  platelet-derived
growth  factor  receptor-β (PDGFR-β,  1:100,
Calbiochem,  Schwalbach/Ts,  Germany),  and
stem  cell  tyrosine  kinase  1  (FLT3,  1:100,
Abcam, Cambridge, UK), as well as CD31 (1:25,
Dako)  and  MIB1  (1:200,  Dako),  using  the
EnVision™  system  (Dako)  according  to  the
manufacturers’ instructions. With the excep-
tion of VEGFR2 staining (EDTA buffer, pH 9.0),
all slides were pretreated with citrate buffer
(pH  6.1).  Respective  positive  controls  were
used for all staining (VEGFR2: ductal invasive
breast carcinoma; c-kit: skin; PDGFR-β: skin;
FLT3:  thymus).  Samples  were  stained  with
hematoxylin-and-eosin  (H/E)  and  carefully
reviewed by the study pathologist (CM). The
specific  immunohistochemical  staining  and
the number of MIB1 positive cells were evalu-
ated semi-quantitatively. Mutational analyses
of c-kit exons 9, 11, 13, 14, and 17 were per-
formed on genomic DNA extracted from paraf-
fin-embedded BRBNS tissue as described pre-
viously.
Results
We report on a 19-year-old male with multi-
ple, slowly growing, cutaneous malformations,
predominantly  in  mechanically  stressed
regions of the skin (feet, waist). Initially, the
boy  presented  early  after  birth  with  a  large
hemangioma of the right shoulder resulting in
a  diagnosis  of  Kasabach-Merritt  syndrome.
Because glucocorticoid therapy did not result
in  a  clinical  reduction  of  hemangioma  size,
several surgical interventions were attempted.
In subsequent years, additional hemangiomas
developed within dermal tissue. Owing to the
patient’s young age and good compliance, off-
line  targeted  therapeutic  approaches  were
considered in order to improve his quality of
life. H/E-staining revealed multiple sub-epider-
mal  and  differentially  sized  cavernous  hem  -
angiomas (Figure 1A). All analyzed hemangi  -
omas  were  lined  with  CD31-positive  cells
(Figure 1B). Less than 5% of these endothelial
cells stained positively for the nuclear prolifer-
ation marker MIB1 (Figure 1C). In order to
identify growth factor signaling pathways pos-
sibly involved in angiogenesis and vasculogen-
esis of cutaneous lesions in BRBNS patients,
we analyzed the expression of four different
known angiogenic markers including tyrosine
kinases (VEGFR2, c-kit, PDGFR-β, FLT3). No
detectable membranous or cytoplasmic signals
were detected for FLT3, VEGFR2, or PDGFR-β
in the endothelial positive cells of venous mal-
formations, while all controls showed a regular
staining pattern (data not shown). In contrast,
c-kit  showed  positivity  in  the  cytoplasm  of
endothelial cells with preference for smaller
sized  vessels  in  the  venous  malformation
(Figure 1D-F). In order to define whether com-
mon activating mutations participate further
in  the  activation  of  the  SCF/c-kit  pathway,
mutation analysis of the c-kit exons 9, 11, 13,
14, and 17 were performed. No mutations were
detected in these genomic regions. 
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Discussion
The BRBNS (synonym: bean syndrome) is
characterized by slow and permanent growth
of  cavernous  hemangiomas  in  the  skin  and
gastrointestinal mucosa. BRBNS patients suf-
fer from severe complications such as rupture
of larger malformations with potentially life-
threatening intestinal bleeding.
4,7-8 Our results
together with published data suggest that this
moderate but steady increase of vessel size is
based on the low number of dividing endothe-
lial cells.
9
Because the underlying molecular mechan  -
isms of this disease are not understood, no
specific  therapeutic  approaches  have  been
developed  to  date.  Nobuhara  and  colleagues
correlated the presence of an activating muta-
tion in the tyrosine kinase receptor TIE2 (syn-
onym: CD202b, TIE2R849W) with the develop-
ment  of  hemangiomatosis.
6 Although  it  has
been demonstrated that this gain-of-function
mutation is essential for proper venous mor-
phogenesis,
10 additional  data  analyzing  the
potential relevance of other cell growth regu-
lating tyrosine kinases is missing. Therefore,
we systematically analyzed the expression of
known  angiogenic  markers  and  found  that
most  of  these  factors  are  not  expressed  in
CD31 positive cells of hemangiomas. However,
c-kit was detectable predominantly in smaller
sized  vessels  within  the  specimens  of  our
patient, suggesting that the SCF (stem cell fac-
tor)/c-kit signaling axis is involved in the con-
stant  growth  of  the  venous  malformations.
Normal endothelial cells of adult vessels did
not  show  c-kit  expression,  whereas  at  least
partial  c-kit  positivity  has  been  reported  in
angiosarcomas.
11 In  addition,  c-kit  is  indeed
known as a stem cell marker that has also been
described in the context of angiogenesis.
12-14 C-
kit  inhibition  by  selective  small  molecules
such as imatinib mesylate currently represents
the gold standard in the treatment of gastroin-
testinal stromal tumors (GISTs) and hematolo-
gous malignant diseases.
15-17 In addition, a sec-
ond generation of c-kit inhibitors for the treat-
ment of imatinib mesylate-refractory patients
(e.g.  AMG-706  and  AMN-107)  currently  is
being  tested  in  clinical  trials.
17 Although  no
mutations were found in described exons of c-
kit, a remarkable expression of c-kit is notable.
Thus, targeting slowly cycling endothelial cells
using c-kit-specific inhibitors might represent
a  novel  therapeutic  option  for  BRNBS  or
patients with smaller and slowly progressing
lesions. 
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Figure 1. Histopathology
and  immunohistochem  -
ical  analyses  of  resected
hemangioma  specimen.
(A)  Conventional  H/E
staining  of  cavernous
hemangiomas. Immuno  -
histochemical  staining
with (B) the endothelial
cell  marker  CD31,  and
(C) the nuclear prolifera-
tion  marker  MIB1
(arrow: positive cell). (D-
F)  Staining  of  c-kit
revealed  an  exclusive
staining  in  endothelial
cells of intermediate and
small  venous  malforma-
tions (arrows) but not of
larger sized vessels. Note
inflammatory  cells  as
internal  positive  control
(arrowhead).  Scale  bars:
100 µm.